An open-label, randomized trial of the combination of IFN-κ plus TFF2 with standard care in the treatment of patients with moderate COVID-19

von Fu, Weihui, Liu, Yan, Liu, Li, Hu, Huiliang, Cheng, Xiaobo, Liu, Ping, Song, Zhigang, Zha, Lijun, Bai, Shimeng, Xu, Tingting, Yuan, Songhua, Lu, Fengru, Shang, Zhiying, Zhao, Yihong, Wang, Jing, Zhao, Jun, Ding, Longfei, Chen, Jun, Zhang, Lin, Zhu, Tongyu, Zhang, Xiaoyan, Lu, Hongzhou, Xu, Jianqing
Veröffentlicht in EClinicalMedicine (2020)